OPDIVO (NIVOLUMAB) INJECTION

OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Drug type: Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody. (For more detail, see “How this drug works,” below.)

What this drug is used for:

• For the treatment of patients with unresectable or metastatic melanoma and disease progression in combination with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
• For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
• Treatment of advanced renal cell cancer in patients who have received prior anti-angiogenic therapy.
• Treatment of patients with classical Hodgkins lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.